News stories about Arrowhead Pharmaceuticals (NASDAQ:ARWR) have trended somewhat positive this week, Accern Sentiment Analysis reports. The research firm ranks the sentiment of news coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Arrowhead Pharmaceuticals earned a daily sentiment score of 0.21 on Accern’s scale. Accern also assigned news stories about the biotechnology company an impact score of 45.0036462044964 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
Arrowhead Pharmaceuticals (NASDAQ ARWR) opened at 3.90 on Thursday. Arrowhead Pharmaceuticals has a 12 month low of $1.20 and a 12 month high of $6.99. The stock’s market cap is $291.61 million. The company has a 50-day moving average of $3.67 and a 200-day moving average of $2.20.
Arrowhead Pharmaceuticals (NASDAQ:ARWR) last released its quarterly earnings data on Thursday, August 3rd. The biotechnology company reported ($0.07) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.13) by $0.06. Arrowhead Pharmaceuticals had a negative net margin of 201.84% and a negative return on equity of 46.73%. The business had revenue of $9.34 million during the quarter, compared to analyst estimates of $5.29 million. On average, equities analysts forecast that Arrowhead Pharmaceuticals will post ($0.42) EPS for the current fiscal year.
A number of analysts have recently issued reports on ARWR shares. ValuEngine downgraded shares of Arrowhead Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Friday, September 1st. William Blair raised shares of Arrowhead Pharmaceuticals from a “market perform” rating to an “outperform” rating in a report on Monday, September 18th. Cantor Fitzgerald reaffirmed a “hold” rating and set a $2.00 price objective (up from $1.00) on shares of Arrowhead Pharmaceuticals in a report on Friday, September 15th. Piper Jaffray Companies reaffirmed a “hold” rating and set a $2.00 price objective on shares of Arrowhead Pharmaceuticals in a report on Friday, July 28th. Finally, Chardan Capital reaffirmed a “neutral” rating on shares of Arrowhead Pharmaceuticals in a report on Wednesday, September 13th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and one has given a buy rating to the stock. Arrowhead Pharmaceuticals currently has an average rating of “Hold” and an average price target of $2.00.
COPYRIGHT VIOLATION NOTICE: “Arrowhead Pharmaceuticals (ARWR) Given Media Sentiment Score of 0.21” was originally posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this report on another domain, it was copied illegally and republished in violation of US and international copyright & trademark legislation. The legal version of this report can be accessed at https://ledgergazette.com/2017/10/19/arrowhead-pharmaceuticals-arwr-given-media-sentiment-score-of-0-21.html.
About Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals, Inc, formerly Arrowhead Research Corporation, develops medicines that treat intractable diseases by silencing the genes that cause them. Using a portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, the Company’s therapies trigger the RNA interference mechanism to induce knockdown of target genes.